July 22, 2022. Brian Strem, PhD, CEO of Kiora Pharmaceuticals, talks to Ben Shaberman about his company's emerging gene-agnostic small molecule for restoring vision for people with advanced retinitis pigmentosa and potentially other retinal diseases. Kiora recently received authorization in Australia to launch a trial for the treatment.